Antibody Therapies

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2 Market Segmentation
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Overview of Novel Antibody Therapies
3.2. Types of Novel Antibody Therapies
3.2.1. Antibody-Directed Enzyme Prodrug Therapy (ADEPT)
3.2.1.1. Mechanism of Action of ADEPT
3.2.1.2. Advantages of ADEPT
3.2.1.3. Disadvantages of ADEPT

3.2.2. TCR like Antibodies
3.2.2.1. Mechanism of Action of TCR like Antibodies
3.2.2.2. Advantages of TCR like Antibodies
3.2.2.3. Disadvantages of TCR like Antibodies

3.2.3. Radioisotope Immunoconjugates
3.2.3.1. Mechanism of Action of Radioisotope Immunoconjugates
3.2.3.2. Advantages of Radioisotope Immunoconjugates
3.2.3.3. Disadvantages of Radioisotope Immunoconjugates

3.2.4. Immunotoxins
3.2.4.1. Mechanism of Action of Immunotoxins
3.2.4.2. Advantages of Immunotoxins
3.2.4.3. Disadvantages of Immunotoxins

3.2.5. Intracellular Antibody
3.2.5.1. Mechanism of Action of Intracellular Antibody
3.2.5.2. Advantages of Intracellular Antibody
3.2.5.3. Disadvantages of Intracellular Antibody

3.2.6. Immunocytokines
3.2.6.1. Mechanism of Action of Immunocytokines
3.2.6.2. Advantages of Immunocytokines
3.2.6.3. Disadvantages of Immunocytokines

3.3. Therapeutic Antibodies: Development Approaches
3.4. Future Perspectives

4. NOVEL ANTIBODY THERAPIES: MARKET LANDSCAPE
4.1. Analysis Methodology and Key Parameters
4.2. Novel Antibody Therapies: Development Pipeline (Immunocytokines)
4.2.1. Analysis by Status of Development
4.2.2. Analysis by Mechanism of Action
4.2.3. Analysis by Type of Cytokine
4.2.4. Analysis by Status of Development and Type of Cytokine
4.2.5. Analysis by Type of Antigen / Format
4.2.6. Analysis by Dosing Frequency
4.2.7. Analysis by Type of Therapy
4.2.8. Analysis by Mode of Administration
4.2.9. Analysis by Route of Administration
4.2.10. Analysis by Target Disease Indication(s)

4.3. Novel Antibody Therapies: Development Pipeline (Immunotoxins)
4.3.1. Analysis by Status of Development
4.3.2. Analysis by Mechanism of Action
4.3.3. Analysis by Type of Toxin
4.3.4. Analysis by Dosing Frequency
4.3.5. Analysis by Type of Therapy
4.3.6. Analysis by Mode of Administration
4.3.7. Analysis by Immunotoxin Target
4.3.8. Analysis by Special Drug Designation
4.3.9. Analysis by Route of Administration
4.3.10. Analysis by Target Disease Indication(s)

4.4. Novel Antibody Therapies: Development Pipeline (Radioisotope Immunoconjugates)
4.4.1. Analysis by Status of Development
4.4.2. Analysis by Type of Radio Isotopes
4.4.3. Analysis by Status of Development and Type of Radio Isotopes
4.4.4. Analysis by Route of Administration
4.4.5. Analysis by Type of Therapy
4.4.6. Analysis by Dosing Frequency
4.4.7. Analysis by Mode of Administration
4.4.8. Analysis by Special Drug Designation
4.4.9. Analysis by Target Disease Indication(s)

4.5. Novel Antibody Therapies: Development Pipeline (Other Novel Antibody)
4.6. Novel Antibody Therapies: List of Developers
4.6.1. Analysis by Type of Player
4.6.2. Analysis by Company Size
4.6.3. Analysis by Year of Establishment
4.6.4. Analysis by Company Size and Region of Headquarters
4.6.5. Leading Players: Analysis by Number of Therapeutics
4.6.6. Analysis by Location of Headquarters (Region-wise)
4.6.7. Analysis by Location of Headquarters (Country-wise)

5. COMPANY PROFILES
5.1. Actinium Pharmaceuticals
5.1.1. Company Overview
5.1.2. Financial Information
5.1.3. Product Portfolio
5.1.4. Recent Developments and Future Outlook

5.2. Molecular Templates
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Product Portfolio
5.2.4. Recent Developments and Future Outlook

5.3. Philogen
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. Product Portfolio
5.3.4. Recent Developments and Future Outlook

5.4. Roche
5.4.1. Company Overview
5.4.2. Financial Information
5.4.3. Product Portfolio
5.4.4. Recent Developments and Future Outlook

5.5. Seagen
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. Product Portfolio
5.5.4. Recent Developments and Future Outlook

5.6. Sesen bio
5.6.1. Company Overview
5.6.2. Financial Information
5.6.3. Product Portfolio
5.6.4. Recent Developments and Future Outlook

5.7. Telix Pharmaceuticals
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. Product Portfolio
5.7.4. Recent Developments and Future Outlook

5.8. Y-mAbs Therapeutics
5.8.1. Company Overview
5.8.2. Financial Information
5.8.3. Product Portfolio
5.8.4. Recent Developments and Future Outlook

6. CLINICAL TRIAL ANALYSIS
6.1. Analysis Methodology and Key Parameters
6.2. List of Clinical Trials Focused on Novel Antibody Therapies
6.2.1. Analysis by Trial Status
6.2.2. Analysis by Trial Registration Year
6.2.3. Analysis by Trial Registration Year and Trial Status
6.2.4. Analysis by Trial Phase
6.2.5. Analysis by Trial Phase and Patients Enrolled
6.2.6. Analysis by Trial Registration Year and Patients Enrolled
6.2.7. Analysis by Type of Sponsor / Collaborator
6.2.8. Analysis by Disease Indication(s)
6.2.9. Analysis by Study Design
6.2.10. Most Active Industry Players: Analysis by Number of Trials
6.2.11. Most Active Non-Industry Players: Analysis by Number of Trials
6.2.12. Analysis by Type of Treatment
6.2.13. Analysis by Type of Drug
6.2.14. Word Cloud Analysis: Emerging Focus Areas
6.2.15. Analysis by Top Indication(s) and Trial Phase
6.2.16. Analysis by Top Indication(s) and Leading Industry Players
6.2.17. Analysis by Trial Location
6.2.18. Analysis by Geography and Trial Status

7. PUBLICATION ANALYSIS
7.1. Analysis Methodology and Key Parameters
7.2. List of Publications Focused on Novel Antibody Therapies
7.2.1. Analysis by Year of Publication
7.2.2. Word Cloud Analysis: Emerging Focus Areas
7.2.3. Analysis by Type of Article

7.2.4. Key Journals: Analysis by Number of Publications
7.2.5. Key Journals: Analysis by Impact Factor
7.2.6. Most Popular Publishers: Analysis by Number of Publications
7.2.7. Most Popular Copyright Holders: Analysis by Number of Publications

8. PATENT ANALYSIS
8.1. Analysis Methodology and Key Parameters
8.2. List of Patents Focused on Novel Antibody Therapies
8.2.1. Analysis by Patent Publication Year
8.2.2. Year-wise Trend of Granted Patents
8.2.3. Analysis by Type of Patent
8.2.4. Analysis by Granted Patents and Patent Applications
8.2.5. Analysis by Geography
8.2.6. Analysis by CPC Symbols
8.2.7. Analysis by Type of Applicant
8.2.8. Analysis by Patent Age
8.2.9. Word Cloud Analysis: Emerging Focus Areas
8.2.10. Leading Industry Players: Analysis by Number of Patents
8.2.11. Leading Non-Industry Players: Analysis by Number of Patents
8.2.12. Leading Individual Assignees: Analysis by Number of Patents
8.2.13. Leading Players: Benchmarking by Patent Characteristics (CPC Symbols)
8.2.14. Patent Valuation: Analysis Methodology and Parameters
8.2.15. Patent Valuation: Analysis by Relative Valuation

9. PARTNERSHIPS AND COLLABORATIONS
9.1. List of Partnerships and Collaborations Focused on Novel Antibody Therapies
9.1.1. Analysis by Year of Partnership
9.1.2. Analysis by Type of Partnership
9.1.3. Analysis by Year and Type of Partnership
9.1.4. Most Popular Drug: Analysis by Number of Partnerships
9.1.5. Analysis by Types of Novel Antibodies
9.1.6. Analysis by Type of Partner
9.1.7. Analysis by Partner Company and Type of Partnership
9.1.8. Analysis by Popular Disease Indication(s)
9.1.9. Analysis by Popular Disease Indication and Type of Partnership
9.1.10. Regional Analysis of Partnerships
9.1.11. Intercontinental and Intracontinental Agreements

10. BIG PHARMA PLAYERS
10.1 Analysis Methodology and Key Parameters
10.2. List of Big Pharma Players Focused on Novel Antibody Therapies 
10.3. Scoring Criteria for Key Parameters 
10.3.1. Analysis by Supplier Strength
10.3.2. Analysis by Portfolio Strength
10.3.3. Analysis by Portfolio Diversity
10.3.4. Benchmarking: Spider Web Analysis
10.3.5. Benchmarking: Harvey Ball Analysis
10.3.6. Benchmarking: Wind Rose Chart

11. MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. Forecast Methodology and Key Assumptions
11.2. Global Novel Antibody Therapies Market, 2022-2035
11.3. Product-wise Sales Forecast (Marketed Drugs)
11.3.1. Adcetris (Seagen)
11.3.1.2. Sales Forecast

11.3.2. Elzonris (Menarini Group)
11.3.2.2. Sales Forecast
11.3.3. Pluvicto (Novartis)
11.3.3.2. Sales Forecast

11.4. Global Novel Antibody Therapies Market, 2024 and 2035: Distribution by Type of Novel Antibodies
11.4.1 Novel Antibody Therapies Market for Immunocytokines, 2024-2035
11.4.2 Novel Antibody Therapies Market for Immunotoxin, 2023-2035
11.4.3 Novel Antibody Therapies Market for Radioisotopes Immunoconjugates, 2023-2035

11.5. Global Novel Antibody Therapies Market, 2026 and 2035: Distribution by Target Disease Indication(s)
11.5.1 Novel Antibody Therapies Market for Acute Myeloid Leukemia, 2023-2035
11.5.2 Novel Antibody Therapies Market for Bladder Cancer, 2023-2035
11.5.3 Novel Antibody Therapies Market for Diffuse Large B-cell Lymphoma, 2025-2035
11.5.4 Novel Antibody Therapies Market for Graft-versus-host disease, 2026-2035
11.5.5 Novel Antibody Therapies Market for Melanoma, 2024-2035
11.5.6 Novel Antibody Therapies Market for Prostate Cancer, 2026-2035
11.5.7 Novel Antibody Therapies Market for Soft-tissue sarcoma, 2025-2035

11.6. Global Novel Antibody Therapies Market, 2024 and 2035: Distribution by Type of Therapy
11.6.1. Novel Antibody Therapies Market for Combination Therapy, 2024-2035
11.6.2. Novel Antibody Therapies Market for Monotherapy, 2023-2035

11.7. Global Novel Antibody Therapies Market, 2023 and 2035: Distribution by Route of Administration
11.7.1. Novel Antibody Therapies Market for Intratumoral Drugs, 2023-2035
11.7.2. Novel Antibody Therapies Market for Intravenous Drugs, 2023-2035
11.7.3. Novel Antibody Therapies Market for Intravesical Drugs, 2023-2035

11.8. Global Novel Antibody Therapies Market, 2024 and 2035: Distribution by Geography
11.8.1. Novel Antibody Therapies Market in North America, 2023-2035
11.8.2. Novel Antibody Therapies Market in Europe, 2025-2035
11.8.3. Novel Antibody Therapies Market in Asia Pacific, 2023-2035

11.9. Product-wise Sales Forecast (Phase III Drugs)
11.9.1. Adcetris (Seagen)
11.9.1.1. Target Patient Population
11.9.1.2. Sales Forecast
11.9.1.3. Net Present Value
11.9.1.4. Value Creation Analysis

11.9.2. Fibromun (Philogen)
11.9.2.1. Target Patient Population
11.9.2.2. Sales Forecast
11.9.2.3. Net Present Value
11.9.2.4. Value Creation Analysis

11.9.3. Iomab-B (Actinium Pharmaceuticals)
11.9.3.1. Target Patient Population
11.9.3.2. Sales Forecast
11.9.3.3. Net Present Value
11.9.3.4. Value Creation Analysis

11.9.4. Nidlegy (Philogen)
11.9.4.1. Target Patient Population
11.9.4.2. Sales Forecast
11.9.4.3. Net Present Value
11.9.4.4. Value Creation Analysis

11.9.5. T-Guard (Xenikos)
11.9.5.1. Target Patient Population
11.9.5.2. Sales Forecast
11.9.5.3. Net Present Value
11.9.5.4. Value Creation Analysis

11.9.6. TLX 591 (Telix Pharmaceuticals)
11.9.6.1. Target Patient Population
11.9.6.2. Sales Forecast
11.9.6.3. Net Present Value
11.9.6.4. Value Creation Analysis

11.9.7. Vicinium (Sesen Bio)
11.9.7.1. Target Patient Population
11.9.7.2. Sales Forecast
11.9.7.3. Net Present Value
11.9.7.4. Value Creation Analysis

12. APPENDIX 1: TABULATED DATA

13. APPNEDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Types of Novel Antibody Therapies
Figure 3.2 Mechanism of Action of ADEPT
Figure 3.3 Mechanism of Action of TCR like Antibodies
Figure 3.4 Mechanism of Action of Radioisotope Immunoconjugates
Figure 3.5 Mechanism of Action of Immunotoxins
Figure 3.6 Mechanism of Action of Intracellular Antibody
Figure 3.7 Mechanism of Action of Immunocytokines
Figure 3.8 Therapeutic Antibodies: Development Approaches
Figure 4.1 Immunocytokines: Distribution by Status of Development
Figure 4.2 Immunocytokines: Distribution by Mechanism of Action
Figure 4.3 Immunocytokines: Distribution by Type of Cytokine
Figure 4.4 Immunocytokines: Distribution by Status of Development and Type of Cytokine
Figure 4.5 Immunocytokines: Distribution by Type of Antigen / Format
Figure 4.6 Immunocytokines: Distribution by Dosing Frequency
Figure 4.7 Immunocytokines: Distribution by Type of Therapy
Figure 4.8 Immunocytokines: Distribution by Mode of Administration
Figure 4.9 Immunocytokines: Distribution by Route of Administration
Figure 4.10 Immunocytokines: Distribution by Target Disease Indication(s)
Figure 4.11 Immunotoxins: Distribution by Status of Development
Figure 4.12 Immunotoxins: Distribution by Mechanism of Action
Figure 4.13 Immunotoxins: Distribution by Type of Toxin
Figure 4.14 Immunotoxins: Distribution by Dosing Frequency
Figure 4.15 Immunotoxins: Distribution by Type of Therapy
Figure 4.16 Immunotoxins: Distribution by Mode of Administration
Figure 4.17 Immunotoxins: Distribution by Immunotoxin Target
Figure 4.18 Immunotoxins: Distribution by Special Drug Designation
Figure 4.19 Immunotoxins: Distribution by Route of Administration
Figure 4.20 Immunotoxins: Distribution by Target Disease Indication(s)
Figure 4.21 Radioisotope Immunoconjugates: Distribution by Status of Development
Figure 4.22 Radioisotope Immunoconjugates: Distribution by Type of Radio Isotopes
Figure 4.23 Radioisotope Immunoconjugates: Distribution by Status of Development and Type of Radio Isotopes
Figure 4.24 Radioisotope Immunoconjugates: Distribution by Route of Administration
Figure 4.25 Radioisotope Immunoconjugates: Distribution by Type of Therapy
Figure 4.26 Radioisotope Immunoconjugates: Distribution by Dosing Frequency
Figure 4.27 Radioisotope Immunoconjugates: Distribution by Mode of Administration
Figure 4.28 Radioisotope Immunoconjugates: Distribution by Special Drug Designation
Figure 4.29 Radioisotope Immunoconjugates: Distribution by Target Disease Indication(s)
Figure 4.30 Novel Antibody Therapies Developers: Distribution by Type of Player
Figure 4.31 Novel Antibody Therapies Developers: Distribution by Company Size
Figure 4.32 Novel Antibody Therapies Developers: Distribution by Year of Establishment
Figure 4.33 Novel Antibody Therapies Developers: Distribution by Company Size and Region of Headquarters
Figure 4.34 Leading Players: Distribution by Number of Therapeutics
Figure 4.35 Novel Antibody Therapies Developers: Distribution by Location of Headquarters (Region-wise)
Figure 4.36 Novel Antibody Therapies Developers: Distribution by Location of Headquarters (Country-wise)
Figure 5.1 Molecular Templates: Financial Information (2016- H1 2022)
Figure 5.2 Philogen: Financial Information (2017- H1 2022)
Figure 5.3 Roche: Financial Information (2016- H1 2022)
Figure 5.4 Seagen: Financial Information (2016- H1 2022)
Figure 5.5 Sesen bio: Financial Information (2020-2021)
Figure 5.6 Telix Pharmaceuticals: Financial Information (2018- H1 2022)
Figure 5.7 Y-mAbs Therapeutics: Financial Information (2020- H1 2022)
Figure 6.1 Clinical Trial Analysis: Distribution by Trial Status
Figure 6.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, (Pre-2016-April 2022)
Figure 6.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, (Pre-2001- April 2022)
Figure 6.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 6.5 Clinical Trial Analysis: Distribution by Trial Phase and Patients Enrolled
Figure 6.6 Clinical Trial Analysis: Distribution by Trial Registration Year and Patients Enrolled
Figure 6.7 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 6.8 Clinical Trial Analysis: Distribution by Disease Indication(s)
Figure 6.9 Clinical Trial Analysis: Distribution by Study Design
Figure 6.10 Most Active Industry Players: Distribution by Number of Trials
Figure 6.11 Most Active Non-Industry Players: Distribution by Number of Trials
Figure 6.12 Clinical Trial Analysis: Distribution by Type of Treatment
Figure 6.13 Clinical Trial Analysis: Distribution by Type of Drug
Figure 6.14 Word Cloud Analysis: Emerging Focus Areas
Figure 6.15 Clinical Trial Analysis: Distribution by Top Indication(s) and Trial Phase
Figure 6.16 Clinical Trial Analysis: Distribution by Top Indication(s) and Leading Industry Players
Figure 6.17 Clinical Trial Analysis: Distribution by Trial Location
Figure 6.18 Clinical Trial Analysis: Distribution by Geography and Trial Status
Figure 7.1 Publication Analysis: Distribution by Year of Publication
Figure 7.2 Word Cloud Analysis: Emerging Focus Areas
Figure 7.3 Publication Analysis: Distribution by Type of Article
Figure 7.4 Key Journals: Distribution by Number of Publications
Figure 7.5 Key Journals: Distribution by Impact Factor
Figure 7.6 Most Popular Publishers: Distribution by Number of Publications
Figure 7.7 Most Popular Copyright Holders: Distribution by Number of Publications
Figure 8.1 Patent Analysis: Distribution by Patent Publication Year
Figure 8.2 Patent Analysis: Year-wise Distribution of Granted Patents
Figure 8.3 Patent Analysis: Distribution by Type of Patent
Figure 8.4 Patent Analysis: Distribution by Granted Patents and Patent Applications
Figure 8.5 Patent Analysis: Distribution by Geography
Figure 8.6 Patent Analysis: Distribution by CPC Symbols
Figure 8.7 Patent Analysis: Distribution by Type of Applicant
Figure 8.8 Patent Analysis: Distribution of Patents by Age
Figure 8.9 Word Cloud Analysis: Emerging Focus Areas
Figure 8.10 Leading Industry Players: Distribution by Number of Patents
Figure 8.11 Leading Non-Industry Players: Distribution by Number of Patents
Figure 8.12 Leading Individual Assignees: Distribution by Number of Patents
Figure 8.13 Leading Players: Benchmarking by Patent Characteristics (CPC Symbols)
Figure 8.14 Patent Valuation: Distribution by Relative Valuation
Figure 9.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 9.4 Most Popular Drug: Distribution by Number of Partnerships
Figure 9.5 Partnerships and Collaborations: Distribution by Types of Novel Antibodies
Figure 9.6 Partnerships and Collaborations: Distribution by Type of Partner
Figure 9.7 Partnerships and Collaborations: Distribution by Partner Company and Type of Partnership
Figure 9.8 Partnerships and Collaborations: Distribution by Popular Disease Indication(s)
Figure 9.9 Partnerships and Collaborations: Distribution by Popular Disease Indication(s) and Type of Partnership
Figure 9.10 Regional Distribution of Partnerships
Figure 9.11 Intercontinental and Intracontinental Agreements
Figure 10.1 Distribution by Supplier Strength
Figure 10.2 Distribution by Portfolio Strength
Figure 10.3 Distribution by Portfolio Diversity
Figure 10.4 Benchmarking: Spider Web Analysis
Figure 10.5 Benchmarking: Harvey Ball Analysis
Figure 10.6 Benchmarking: Wind Rose Chart
Figure 11.1 Global Novel Antibody Therapies Market, 2022-2035 (USD Billion)
Figure 11.2 Adcetris Sales Forecast, 2022-2035 (USD Billion)
Figure 11.3 Elzonris Sales Forecast, 2022-2035 (USD Billion)
Figure 11.4 Pluvicto Sales Forecast, 2022-2035 (USD Billion)
Figure 11.5 Global Novel Antibody Therapies Market, 2022 and 2035: Distribution by Type of Novel Antibodies
Figure 11.6 Novel Antibody Therapies Market for Immunocytokines, 2022-2035 (USD Billion)
Figure 11.7 Novel Antibody Therapies Market for Immunotoxin, 2022-2035 (USD Billion)
Figure 11.8 Novel Antibody Therapies Market for Radioisotopes Immunoconjugates, 2022-2035 (USD Billion)
Figure 11.9 Global Novel Antibody Therapies Market, 2022 and 2035: Distribution by Target Disease Indication(s)
Figure 11.10 Novel Antibody Therapies Market for Acute Myeloid Leukemia, 2022-2035 (USD Billion)
Figure 11.11 Novel Antibody Therapies Market for Bladder Cancer, 2022-2035 (USD Billion)
Figure 11.12 Novel Antibody Therapies Market for Diffuse Large B-cell Lymphoma, 2022-2035 (USD Billion)
Figure 11.13 Novel Antibody Therapies Market for Graft-versus-host disease, 2022-2035 (USD Billion)
Figure 11.14 Novel Antibody Therapies Market for Melanoma, 2022-2035 (USD Billion)
Figure 11.15 Novel Antibody Therapies Market for Prostate Cancer, 2022-2035 (USD Billion)
Figure 11.16 Novel Antibody Therapies Market for Soft-tissue sarcoma, 2022-2035 (USD Billion)
Figure 11.17 Global Novel Antibody Therapies Market, 2022 and 2035: Distribution by Type of Therapy
Figure 11.18 Novel Antibody Therapies Market for Combination Therapy, 2022-2035 (USD Billion)
Figure 11.19 Novel Antibody Therapies Market for Monotherapy, 2022-2035 (USD Billion)
Figure 11.20 Global Novel Antibody Therapies Market, 2022 and 2035: Distribution by Route of Administration
Figure 11.21 Novel Antibody Therapies Market for Intratumoral Drugs, 2022-2035 (USD Billion)
Figure 11.22 Novel Antibody Therapies Market for Intravenous Drugs, 2022-2035 (USD Billion)
Figure 11.23 Novel Antibody Therapies Market for Intravesical Drugs, 2022-2035 (USD Billion)
Figure 11.24 Global Novel Antibody Therapies Market, 2022 and 2035: Distribution by Geography
Figure 11.25 Novel Antibody Therapies Market in North America, 2022-2035 (USD Billion)
Figure 11.26 Novel Antibody Therapies Market in Europe, 2022-2035 (USD Billion)
Figure 11.27 Novel Antibody Therapies Market in Asia Pacific, 2022-2035 (USD Billion)
Figure 11.28 Adcetris: Target Patient Population
Figure 11.29 Adcetris Sales Forecast, 2022-2035 (USD Billion)
Figure 11.30 Fibromun: Target Patient Population
Figure 11.31 Fibromun Sales Forecast, 2022-2035 (USD Billion)
Figure 11.32 Iomab-B: Target Patient Population
Figure 11.33 Iomab-B Sales Forecast, 2022-2035 (USD Billion)
Figure 11.34 Nidlegy: Target Patient Population
Figure 11.35 Nidlegy Sales Forecast, 2022-2035 (USD Billion)
Figure 11.36 T-Guard: Target Patient Population
Figure 11.37 T-Guard Sales Forecast, 2022-2035 (USD Billion)
Figure 11.38 TLX 591: Target Patient Population
Figure 11.39 TLX 591 Sales Forecast, 2022-2035 (USD Billion)
Figure 11.40 Vicinium: Target Patient Population
Figure 11.41 Vicinium Forecast, 2022-2035 (USD Billion)

List Of Tables

Table 4.1 Novel Antibody Therapies (Immunocytokines): Development Pipeline
Table 4.2 Novel Antibody Therapies (Immunotoxins): Development Pipeline
Table 4.3 Novel Antibody Therapies (Radioisotope immunoconjugates): Development Pipeline
Table 4.4 Novel Antibody Therapies (Other Antibodies): Development Pipeline
Table 4.5 Novel Antibody Therapies: List of Developers
Table 5.1 Actinium Pharmaceuticals: Product Portfolio
Table 5.2 Recent Developments and Future Outlook
Table 5.3 Molecular Templates: Product Portfolio
Table 5.4 Recent Developments and Future Outlook
Table 5.5 Philogen: Product Portfolio
Table 5.6 Recent Developments and Future Outlook
Table 5.7 Roche: Product Portfolio
Table 5.8 Recent Developments and Future Outlook
Table 5.9 Seagen: Product Portfolio
Table 5.10 Recent Developments and Future Outlook
Table 5.11 Sesen bio: Product Portfolio
Table 5.12 Recent Developments and Future Outlook
Table 5.13 Telix Pharmaceuticals: Product Portfolio
Table 5.14 Recent Developments and Future Outlook
Table 5.15 Y-mAbs Therapeutics: Product Portfolio
Table 5.16 Recent Developments and Future Outlook
Table 6.1 List of Clinical Trials focused on Novel Antibody Therapies (Pre-2016-2022)
Table 7.1 List of Publications focused on Novel Antibody Therapies (2017-2022)
Table 8.1 List of Patents focused on Novel Antibody Therapies (2017-2022)
Table 9.1 Novel Antibody Therapies: List of Partnerships and Collaborations (2014-2021)
Table 10.1 List of Big Pharma Player Focused on Novel Antibody Therapies
Table 11.1 Adcetris: Target Patient Population
Table 11.2 Adcetris: Net Present Value (USD Billion)
Table 11.3 Elzonris: Target Patient Population
Table 11.4 Elzonris: Net Present Value (USD Billion)
Table 11.5 Fibromun: Target Patient Population
Table 11.6 Fibromun: Net Present Value (USD Billion)
Table 11.7 Iomab-B: Target Patient Population
Table 11.8 Iomab-B: Net Present Value (USD Billion)
Table 11.9 Nidlegy: Target Patient Population
Table 11.10 Nidlegy: Net Present Value (USD Billion)
Table 11.11 Pluvicto: Target Patient Population
Table 11.12 Pluvicto: Net Present Value (USD Billion)
Table 11.13 T-Guard: Target Patient Population
Table 11.14 T-Guard: Net Present Value (USD Billion)
Table 11.15 TLX 591: Target Patient Population
Table 11.16 TLX 591: Net Present Value (USD Billion)
Table 11.17 Vicinium: Target Patient Population
Table 11.18 Vicinium: Net Present Value (USD Billion)
Table 12.1 Immunocytokines: Distribution by Status of Development
Table 12.2 Immunocytokines: Distribution by Mechanism of Action
Table 12.3 Immunocytokines: Distribution by Type of Cytokine
Table 12.4 Immunocytokines: Distribution by Status of Development and Type of Cytokine
Table 12.5 Immunocytokines: Distribution by Type of Antigen / Format
Table 12.6 Immunocytokines: Distribution by Dosing Frequency
Table 12.7 Immunocytokines: Distribution by Type of Therapy
Table 12.8 Immunocytokines: Distribution by Mode of Administration
Table 12.9 Immunocytokines: Distribution by Route of Administration
Table 12.10 Immunocytokines: Distribution by Target Disease Indication(s)
Table 12.11 Immunotoxins: Distribution by Status of Development
Table 12.12 Immunotoxins: Distribution by Mechanism of Action
Table 12.13 Immunotoxins: Distribution by Type of Toxin
Table 12.14 Immunotoxins: Distribution by Dosing Frequency
Table 12.15 Immunotoxins: Distribution by Type of Therapy
Table 12.16 Immunotoxins: Distribution by Mode of Administration
Table 12.17 Immunotoxins: Distribution by Immunotoxin Target
Table 12.18 Immunotoxins: Distribution by Special Drug Designation
Table 12.19 Immunotoxins: Distribution by Route of Administration
Table 12.20 Immunotoxins: Distribution by Target Disease Indication(s)
Table 12.21 Radioisotope Immunoconjugates: Distribution by Status of Development
Table 12.22 Radioisotope Immunoconjugates: Distribution by Type of Radioisotopes
Table 12.23 Radioisotope Immunoconjugates: Distribution by Status of Development and Type of Radioisotopes
Table 12.24 Radioisotope Immunoconjugates: Distribution by Route of Administration
Table 12.25 Radioisotope Immunoconjugates: Distribution by Type of Therapy
Table 12.26 Radioisotope Immunoconjugates: Distribution by Dosing Frequency
Table 12.27 Radioisotope Immunoconjugates: Distribution by Mode of Administration
Table 12.28 Radioisotope Immunoconjugates: Distribution by Special Drug Designation
Table 12.29 Radioisotope Immunoconjugates: Distribution by Target Disease Indication(s)
Table 12.30 Novel Antibody Therapies Developers: Distribution by Type of Players
Table 12.31 Novel Antibody Therapies Developers: Distribution by Company Size
Table 12.32 Novel Antibody Therapies Developers: Distribution by Year of Establishment
Table 12.33 Novel Antibody Therapies Developers: Distribution by Location of Headquarters (Region-wise)
Table 12.34 Novel Antibody Therapies Developers: Distribution by Location of Headquarters (Country-wise)
Table 12.35 Novel Antibody Therapies Developers: Distribution by Company Size and Region of Headquarters
Table 12.36 Leading Players: Distribution by Number of Therapeutics
Table 12.37 Molecular Templates: Financial Information
Table 12.38 Philogen: Financial Information
Table 12.39 Roche: Financial Information
Table 12.40 Seagen: Financial Information
Table 12.41 Sesen bio: Financial Information
Table 12.42 Telix Pharmaceuticals: Financial Information
Table 12.43 Y-mAbs Therapeutics: Financial Information
Table 12.44 Clinical Trial Analysis: Distribution by Trial Status
Table 12.45 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, (Pre-2016-April 2022)
Table 12.46 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, (Pre-2016- April 2022)
Table 12.47 Clinical Trial Analysis: Distribution by Trial Phase
Table 12.48 Clinical Trial Analysis: Distribution by Trial Phase and Patients Enrolled
Table 12.49 Clinical Trial Analysis: Distribution by Trial Registration Year and Patients Enrolled
Table 12.50 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 12.51 Clinical Trial Analysis: Distribution by Disease Indication(s)
Table 12.52 Clinical Trial Analysis: Distribution by Study Design
Table 12.53 Most Active Industry Players: Distribution by Number of Trials
Table 12.54 Most Active Non-Industry Players: Distribution by Number of Trials
Table 12.55 Clinical Trial Analysis: Distribution by Type of Treatment
Table 12.56 Clinical Trial Analysis: Distribution by Type of Drug
Table 12.57 Clinical Trial Analysis: Distribution by Top Indication(s) and Trial Phase
Table 12.58 Clinical Trial Analysis: Distribution by Top Indication(s) and Leading Industry Players
Table 12.59 Clinical Trial Analysis: Distribution by Trial Location
Table 12.60 Clinical Trial Analysis: Distribution by Geography and Trial Status
Table 12.61 Publication Analysis: Distribution by Year of Publication
Table 12.62 Publication Analysis: Distribution by Type of Article
Table 12.63 Top Authors: Distribution by Number of Publications
Table 12.64 Key Journals: Distribution by Number of Publications
Table 12.65 Key Journals: Distribution by Impact Factor
Table 12.66 Most Popular Publishers: Distribution by Number of Publications
Table 12.67 Most Popular Copyright Holders: Distribution by Number of Publications
Table 12.68 Patent Analysis: Distribution by Patent Publication Year
Table 12.69 Patent Analysis: Year-wise Distribution of Granted Patents
Table 12.70 Patent Analysis: Distribution by Type of Patent
Table 12.71 Patent Analysis: Distribution by Granted Patents and Patent Applications
Table 12.72 Patent Analysis: Distribution by Geography
Table 12.73 Patent Analysis: Distribution by CPC Symbols
Table 12.74 Patent Analysis: Distribution by Type of Applicant
Table 12.75 Patent Analysis: Distribution by Patent Age
Table 12.76 Leading Industry Players: Distribution by Number of Patents
Table 12.77 Leading Non-Industry Players: Distribution by Number of Patents
Table 12.78 Leading Individual Assignees: Distribution by Number of Patents
Table 12.79 Leading Players: Benchmarking by Patent Characteristics (CPC Symbols)
Table 12.80 Patent Valuation: Distribution by Relative Valuation
Table 12.81 Partnerships and Collaborations: Distribution by Year of Partnership
Table 12.82 Partnerships and Collaborations: Distribution by Type of Partnership
Table 12.83 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 12.84 Most Popular Drug: Distribution by Number of Partnerships
Table 12.85 Partnerships and Collaborations: Distribution by Types of Novel Antibodies
Table 12.86 Partnerships and Collaborations: Distribution by Target Disease Indication(s)
Table 12.87 Partnerships and Collaborations: Distribution by Type of Partnership and Target Indication(s)
Table 12.88 Most Active Players: Distribution by Number of Partnership
Table 12.89 Partnerships and Collaborations: Distribution by Most Active Partner and Type of Partnership
Table 12.90 Regional Distribution of Partnerships
Table 12.91 Intercontinental and Intracontinental Agreements
Table 12.92 Global Novel Antibody Therapies Market, 2022 and 2035 (USD Billion)
Table 12.93 Adcetris Sales Forecast, 2022-2035 (USD Billion) (Base, Conservative, Optimistic)
Table 12.94 Elzonris Sales Forecast, 2022-2035 (USD Billion) (Base, Conservative, Optimistic)
Table 12.95 Pluvicto Sales Forecast, 2022-2035 (USD Billion) (Base, Conservative, Optimistic)
Table 12.96 Global Novel Antibody Therapies Market, 2022 and 2035: Distribution by Type of Novel Antibodies
Table 12.97 Novel Antibody Therapies Market for Immunocytokines, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.98 Novel Antibody Therapies Market for Immunotoxin, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.99 Novel Antibody Therapies Market for Radioisotopes Immunoconjugates, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.100 Global Novel Antibody Therapies Market, 2022 and 2035: Distribution by Target Disease Indication(s)
Table 12.101 Novel Antibody Therapies Market for Acute Myeloid Leukemia, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.102 Novel Antibody Therapies Market for Bladder Cancer, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.103 Novel Antibody Therapies Market for Diffuse Large B-cell Lymphoma, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.104 Novel Antibody Therapies Market for Graft-versus-host disease, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.105 Novel Antibody Therapies Market for Melanoma, 2022-2035 (USD Billion) (Base, Conservative, Optimistic)
Table 12.106 Novel Antibody Therapies Market for Prostate Cancer, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.107 Novel Antibody Therapies Market for Soft-tissue sarcoma, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.108 Global Novel Antibody Therapies Market, 2022 and 2035: Distribution by Type of Therapy
Table 12.109 Novel Antibody Therapies Market for Combination Therapy, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.110 Novel Antibody Therapies Market for Monotherapy, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion))
Table 12.111 Global Novel Antibody Therapies Market, 2022 and 2035: Distribution by Route of Administration
Table 12.112 Novel Antibody Therapies Market for Intratumoral Drugs, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.113 Novel Antibody Therapies Market for Intravenous Drugs, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.114 Novel Antibody Therapies Market for Intravesical Drugs, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.115 Global Novel Antibody Therapies Market, 2022 and 2035: Distribution by Geography
Table 12.116 Novel Antibody Therapies Market in North America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.117 Novel Antibody Therapies Market in Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.118 Novel Antibody Therapies Market in Asia Pacific Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.119 Adcetris Sales Forecast, 2022-2035 (USD Billion) (Base, Conservative, Optimistic)
Table 12.120 Fibromun Sales Forecast, 2022-2035 (USD Billion) (Base, Conservative, Optimistic)
Table 12.121 Iomab-B Sales Forecast, 2022-2035 (USD Billion) (Base, Conservative, Optimistic)
Table 12.122 Nidlegy Sales Forecast, 2022-2035 (USD Billion) (Base, Conservative, Optimistic)
Table 12.123 T-Guard Sales Forecast, 2022-2035 (USD Billion) (Base, Conservative, Optimistic)
Table 12.124 TLX 591 Sales Forecast, 2022-2035 (USD Billion) (Base, Conservative, Optimistic)
Table 12.125 Vicinium sales Forecast, 2022-2035 (USD Billion) (Base, Conservative, Optimistic)

List Of Companies

The following companies and organizations have been mentioned in the report:

1. 3P Biopharmaceuticals
2. Aachen University Hospital
3. Actinium Pharmaceuticals
4. Active Biotech
5. Adium
6. Alkido Pharma
7. Ajinomoto Bio-Pharma
8. Albert Einstein College of Medicine
9. Alopexx Oncology
10. Angimmune
11. APEIRON Biologics
12. Astellas Pharma
13. AstraZeneca
14. atbtherapeutics
15. Atonco
16. AVEO Oncology
17. Avid Bioservices
18. Bayer
19. Beijing Shenogen Pharmaceutical 
20. Biogen
21. Blood and Marrow Transplant Clinical Trials Network (BMT CTN)
22. Bright Peak Therapeutics
23. Bristol Myers Squibb
24. Cardinal Health
25. City of Hope Medical Center
26. Dana-Farber Cancer Institute
27. Duke University
28. Eastern Hepatobiliary Surgery Hospital (EHBH)
29. Eckert & Ziegler
30. Eczac?ba??-Monrol
31. Eli Lilly
32. EMD Serono
33. EpicentRx
34. Eureka Therapeutics
35. Evergreen Theragnostics
36. Fred Hutchinson Cancer Research Center
37. FUJIFILM Pharmaceuticals U.S.A.
38. Fusion Pharmaceuticals
39. Genentech
40. GenesisCare
41. Genmab
42. Geno Pharmaceuticals
43. Gilead Sciences
44. Global Medical Solutions
45. Grand Pharmaceutical
46. Great Ormond Street Hospital for Children NHS Foundation Trust
47. GT Biopharma
48. Heidelberg University Hospital
49. Hikma Pharmaceuticals
50. iBio
51. Idec Pharmaceuticals (merged with Biogen)
52. Immatics Biotechnologies
53. Immedica Pharma
54. Immunomedics
55. Innate Pharma
56. InterX
57. IONETIX
58. Iovance Biotherapeutics
59. ITM Isotope Technologies Munich
60. Janssen Research & Development
61. Kanaph Therapeutics
62. Kettering Health
63. King's College London
64. LifeArc
65. Livzon MABPharm
66. Ludwig Institute for Cancer Research
67. M.D. Anderson Cancer Center
68. Massachusetts General Hospital
69. Massachusetts Institute of Technology (MIT)
70. McMaster University
71. Memorial Sloan Kettering Cancer Center
72. Menarini Group
73. Merck
74. Molecular Templates
75. Nammi Therapeutics
76. NanoMab
77. National Cancer Institute (NCI)
78. National Institute of Allergy and Infectious Diseases (NIAID)
79. National Institute of Health and Medical Research (INSERM)
80. National Institutes of Health Clinical Center (NIHCC)
81. NIOWAVE
82. Nippon Shinyaku
83. Nordic Nanovector
84. NorthStar Medical Radioisotopes
85. Novartis
86. OncoBeta
87. OncoTherapy Science
88. Orano Med
89. Oslo University Hospital
90. Pfizer
91. Philogen
92. POINT Biopharma Global
93. Precirix
94. ProMIS Neurosciences
95. Qilu Pharmaceutical
96. Radiopharm Theranostics
97. Recepta Biopharma
98. Roche 
99. Romagnolo Institute for the Study of Tumors "Dino Amadori"
100. Sanofi
101. SciClone Pharmaceuticals
102. Scripps Research
103. Seagen
104. Sesen Bio
105. SHINE Technologies
106. Stemline Therapeutics
107. Swixx BioPharma
108. Takeda
109. Telix Pharmaceuticals
110. TRIUMF
111. University of California
112. University of Pennsylvania
113. University of Southampton
114. University of Texas
115. USHEALTH
116. Vanderbilt University
117. Vertex Pharmaceuticals
118. Vybion
119. Xenikos
120. Y-mAbs Therapeutics